The role of CETP inhibition in dyslipidemia

Curr Atheroscler Rep. 2007 Aug;9(2):125-33. doi: 10.1007/s11883-007-0008-5.

Abstract

Cholesteryl ester transfer protein (CETP) inhibitors are currently being investigated because of their ability to increase high-density lipoprotein cholesterol levels. In various metabolic settings, the relationship between CETP and lipoprotein metabolism is complex and may depend largely on the concentration of triglyceride-rich lipoproteins. Two CETP inhibitors, JTT-705 and torcetrapib, are in an advanced phase of development. Following hopeful intermediate results, a large endpoint study using torcetrapib has just been discontinued due to increased mortality in torcetrapib-treated subjects. In this review we summarize clinical data on the use of CETP inhibitors.

Publication types

  • Review

MeSH terms

  • Amides
  • Anticholesteremic Agents / adverse effects
  • Anticholesteremic Agents / therapeutic use*
  • Cholesterol Ester Transfer Proteins / antagonists & inhibitors*
  • Cholesterol Ester Transfer Proteins / physiology*
  • Clinical Trials as Topic
  • Dyslipidemias / drug therapy*
  • Esters
  • Female
  • Humans
  • Hyperlipoproteinemia Type II / blood
  • Hypertriglyceridemia / blood
  • Male
  • Quinolines / adverse effects
  • Quinolines / therapeutic use
  • Sulfhydryl Compounds / adverse effects
  • Sulfhydryl Compounds / therapeutic use

Substances

  • Amides
  • Anticholesteremic Agents
  • CETP protein, human
  • Cholesterol Ester Transfer Proteins
  • Esters
  • Quinolines
  • Sulfhydryl Compounds
  • dalcetrapib
  • torcetrapib